265. Lipodystrophy Clinical trials / Disease details


Clinical trials : 116 Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04903847
(ClinicalTrials.gov)
February 2, 20219/10/2020Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir DisproxilChanges in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;ObesityDrug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]Thomas BenfieldNULLRecruiting18 YearsN/AAll126Phase 4Denmark
2NCT04904406
(ClinicalTrials.gov)
October 22, 20209/10/2020Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected IndividualsChanges in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1Hiv;HIV Infections;HIV Cardiomyopathy;Weight Change, Body;HIV Lipodystrophy;Cardiovascular DiseasesDrug: Dolutegravir / Lamivudine Oral TabletThomas BenfieldNULLRecruiting18 YearsN/AAll95Phase 4Denmark
3NCT04340388
(ClinicalTrials.gov)
September 17, 20201/4/2020Contribution of Dolutegravir to Obesity and Cardiovascular DiseaseContribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIVHIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnormality of Adipose Tissue;Body Weight Changes;Body Fat Disorder;HIV-Associated Lipodystrophy SyndromeDrug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIVAugusta UniversityNULLRecruiting18 Years100 YearsAll30Phase 4United States